Results 31 to 40 of about 25,184 (248)

Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker

Indian Journal of Pathology and Microbiology, 2021
Diffuse Midline Glioma-H3K27M mutant is a specific entity added to the 2016 updated WHO classification of CNS tumours that represents the majority of diffuse intrinsic pontine gliomas, although identical tumours are also found elsewhere in the midline ...
Prachi Agarwal, Hema Malini Aiyer
doaj   +1 more source

Liquid biopsy in H3K27M diffuse midline glioma

Neuro-Oncology, 2023
Abstract Diffuse midline glioma (DMG) with H3K27M mutation is an aggressive and difficult to treat pediatric brain tumor. Recurrent gain of function mutations in H3.3 (H3.3A) and H3.1 (H3C2) at the 27th lysine to methionine (H3K27M) are seen in over 2/3 of DMGs, and are associated with a worse prognosis. Due to the anatomical location of
Jina Patel, Rayan Aittaleb, Robert Doherty, Ananya Gera, Benison Lau, Dana Messinger, Jack Wadden, Andrea Franson, Amanda Saratsis, Carl Koschmann   +9 more
openaire   +3 more sources

A longitudinally extensive H3 K27M-mutant diffuse midline glioma in an elderly patient clinically mimicking central nervous system inflammation: a case report

Folia Neuropathologica, 2021
Diffuse midline gliomas, H3 K27M-mutant, World Health Organization (WHO) grade IV represent a distinct glioma entity with a predominantly paediatric presentation and remarkably poor prognosis.
Kristof Babarczy, Zita Reisz, Elza Szabo, Cecilia Rajda, Laszlo Vecsei, Istvan Bodi, Peter Klivenyi, Tibor Hortobagyi, Levente Szalardy   +8 more
doaj   +1 more source

Emerging roles of telomeric chromatin alterations in cancer [PDF]

, 2019
Telomeres, the nucleoprotein structures that cap the ends of eukaryotic chromosomes, play important and multiple roles in tumorigenesis. Functional telomeres need the establishment of a protective chromatin structure based on the interplay between the ...
Biroccio, Annamaria, Cacchione, Stefano, Rizzo, Angela   +2 more
core   +1 more source

Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle

Diagnostics, 2022
Diffuse midline glioma (DMG) is a heterogeneous group of aggressive pediatric brain tumors with a fatal prognosis. The biological hallmark in the major part of the cases is H3K27 alteration. Prognosis remains poor, with median survival ranging from 9 to 12 months from diagnosis.
Valentina Di Ruscio, Giada Del Baldo, Francesco Fabozzi, Maria Vinci, Antonella Cacchione, Emmanuel de Billy, Giacomina Megaro, Andrea Carai, Angela Mastronuzzi   +8 more
openaire   +3 more sources

Duplications of KIAA1549 and BRAF screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for KIAA1549-BRAF fusion detection in pilocytic astrocytomas [PDF]

, 2018
Pilocytic astrocytomas represent the most common glioma subtype in young patients and account for 5.4% of all gliomas. They are characterized by alterations in the RAS–MAP kinase pathway, the most frequent being a tandem duplication on chromosome 7q34 ...
Appay, Romain, Badiali, Manuela, Barets, Doriane, Colin, Carole, Figarella-Branger, Dominique, Fina, Frédéric, Giangaspero, Felice, Korshunov, Andrey, M. Pfister, Stefan, Macagno, Nicolas, Ordioni, Joanna, Padovani, Laëtitia, Scavarda, Didier, T. W. Jones, David   +13 more
core   +3 more sources

Clinicohistoradiological and Surgical Outcome in Diffuse Midline Glioma

Child's Nervous System, 2023
Abstract Purpose Diffuse midline glioma (DMG) with H3K27M mutation is a rare and aggressive midline high grade glioma with a predominant astrocytic differentiation and K27M mutation in either H3F3A or HIST1H3B/C. This tumor is more common in children than in adults. The current study was aimed to determine clinicohistoradiological and surgical
Arvind Kumar Suman, Suchanda Bhattacharjee, Megha S. Uppin, Syed Tazeem Fathima   +3 more
openaire   +2 more sources

ONC 201 PRACTICE IN DIFFUSE MIDLINE GLIOMA (H3K27M MUTANT)

Hematology, Transfusion and Cell Therapy, 2021
Objective: Diffuse Midline Gliomas (DMG), H3 K27M-mutant have the poorest prognosis among all pediatric high-grade gliomas, with a median survival of 9-11 months.
Bahattin Tanrıkulu, M. Memet Özek, Cengiz Canpolat, Ahmet Harun Yaşar, Ayça Erşen Danyeli   +4 more
doaj   +1 more source

Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial [PDF]

, 2018
The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years.
Brouwer-Visser, Jurriaan, Burford, Anna, Capper, David, Figarella-Branger, Dominique, Garcia, Josep, Garrè, Maria Luisa, Giangaspero, Felice, Grill, Jacques, Haberler, Christine, Izquierdo, Elisa, Jacques, Thomas S., Jaspan, Tim, Jones, Chris, Jones, David T.W., Mackay, Alan, Massimino, Maura, Molinari, Valeria, Morgan, Paul S., Pfister, Stefan M., Pietsch, Torsten, Raman, Pichai, Resnick, Adam C., Rodriguez, Daniel, Smith, Helen, Tam, Rachel, Thakur, Meghna Das, Varlet, Pascale, Varlet, Pascle, Vassal, Gilles, Waanders, Angela J., Würdinger, Thomas   +30 more
core   +7 more sources

Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman

CNS Oncology, 2021
Diffuse midline gliomas harboring histone H3 K27M mutations are most commonly found in the brainstem of children. This mutation confers a WHO grade IV designation and is associated with a particularly poor prognosis.
Justin Thomas Low, Shih-Hsiu Wang, Katherine B Peters   +2 more
doaj   +1 more source